Clinical breast cancer最新文献

{"title":"Impact of COVID-19 Pandemic on Completion of Radiation Therapy After Lumpectomy for Early-Stage Breast Cancer","authors":"Alexandra Stump ,&nbsp;Marie Gordon ,&nbsp;Evan Becker ,&nbsp;Kai Ding ,&nbsp;Shearwood McClelland III","doi":"10.1016/j.clbc.2026.02.004","DOIUrl":"10.1016/j.clbc.2026.02.004","url":null,"abstract":"<div><h3>Background</h3><div>Whole-breast radiation therapy (RT) following lumpectomy has become a standard of care for early-stage breast cancer (ESBC) treatment. Hypofractionated RT (HFRT) has demonstrated equivalent oncologic efficacy to standard fractionation (SFRT). The COVID-19 pandemic accelerated adoption of shorter treatment regimens; however, its impact on RT completion rates and treatment equity has not been well-characterized.</div></div><div><h3>Methods</h3><div>Using the National Cancer Database, patients with ESBC who received post-lumpectomy RT from 2018 to 2022 were identified. SFRT was defined as 1.8-2.0 Gy per fraction and HFRT as 2.66-2.70 Gy per fraction. RT completion was defined as receipt of ≥ 46 Gy for SFRT and ≥ 40 Gy for HFRT. Pre-COVID (2018-2019) and post-COVID (2021-2022) RT completion and HFRT adoption rates were compared using chi-square tests. Adoption and completion were analyzed by race, ethnicity, income, and facility type.</div></div><div><h3>Results</h3><div>Among 25,658 patients (pre-COVID <em>n</em> = 13,381; post-COVID <em>n</em> = 12,277), HFRT use increased from 82.9% to 93.6%, while SFRT declined from 17.1% to 6.4% (<em>P</em> &lt; .0001). Overall RT completion improved from 94.8% to 96.4% (<em>P</em> &lt; .0001). HFRT completion rates remained higher than SFRT (pre-COVID: 97.2% HFRT vs. 83.1% SFRT; post-COVID: 97.5% vs. 80.5%). HFRT adoption increased across all racial and income groups (all <em>P</em> &lt; .0001), with completion exceeding 96% across all subgroups. Racial and income disparities in HFRT differences decreased by a relative reduction of 53.3% and 40.5%, respectively.</div></div><div><h3>Conclusions</h3><div>Post-COVID shifts toward HFRT were associated with higher RT completion and reduced disparities, suggesting more efficient and equitable treatment delivery of adjuvant breast RT.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 4","pages":"Pages 137-143.e2"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147493512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to \"Immunomodulatory Role of Diospyros peregrina Fruit Preparation in Breast Cancer by Utilizing Macrophage Mediated Antigen Presentation and T Helper Cell (Th) Differentiation\" [Clinical Breast Cancer 23 (2023) e95-e102]","authors":"Akshaya Mahalakshmi Surendran ,&nbsp;Akanksha Rai ,&nbsp;Sudeshna Rakshit ,&nbsp;Melvin George ,&nbsp;Koustav Sarkar","doi":"10.1016/j.clbc.2026.03.012","DOIUrl":"10.1016/j.clbc.2026.03.012","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 4","pages":"Page 172"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microsurgery on Steroids: The Impact of Chronic Immunosuppressive Therapy on Outcomes Following Free Flap Breast Reconstruction","authors":"Samuel A. Knoedler ,&nbsp;Thomas Schaschinger ,&nbsp;Tobias Niederegger ,&nbsp;Leonard Knoedler ,&nbsp;Omar Allam ,&nbsp;Felix Klimitz ,&nbsp;Joanna Kempa-Timler ,&nbsp;Karen Lynn Zhao ,&nbsp;Stefano Pompei ,&nbsp;Barbara Kern ,&nbsp;Henriette Grundig ,&nbsp;Giuseppe Sofo ,&nbsp;Francesco Mazzarone ,&nbsp;Fortunay Diatta ,&nbsp;Martin Kauke-Navarro","doi":"10.1016/j.clbc.2026.01.014","DOIUrl":"10.1016/j.clbc.2026.01.014","url":null,"abstract":"<div><h3>Background</h3><div>Free flap breast reconstruction (FFBR) is a well-established technique for postmastectomy rehabilitation. However, chronic immunosuppressive therapy may compromise wound healing, increase infection susceptibility, and adversely affect surgical results. However, evidence regarding the impact of chronic immunosuppression on FFBR outcomes remains sparse.</div></div><div><h3>Methods</h3><div>We analyzed the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database (2013-2023), identifying female breast cancer patients who underwent immediate FFBR. Chronic immunosuppression was defined as continuous systemic administration of corticosteroids or other immunosuppressants for ≥ 30 days preoperatively. Multivariable logistic regression and propensity score matching were applied to assess the impact of immunosuppression on surgical outcomes.</div></div><div><h3>Results</h3><div>Of 5473 patients (mean age 52 ± 9.4 years; mean BMI 30 ± 5.6 kg/m²), 139 (2.5%) were chronically immunosuppressed. In confounder-adjusted multivariable analysis, chronic immunosuppression was independently associated with an increased risk of any complication (OR 1.5; 95% CI, 1.0-2.2; <em>P</em> = .048) and surgical complications (OR 2.0; 95% CI, 1.3-3.0; <em>P</em> = .0011), particularly postoperative bleeding (23% vs. 10%; <em>P</em> &lt; .001). No significant associations were observed with medical complications (<em>P</em> = .73), reoperations (<em>P</em> = .11), or readmissions (<em>P</em> = .45). Propensity score matching validated these correlations, revealing elevated odds of any complications (OR 1.7; <em>P</em> = .044) and surgical complications (OR 2.4; <em>P</em> = .0026) in chronically immunosuppressed patients.</div></div><div><h3>Conclusion</h3><div>Chronic immunosuppression doubles the risk of surgical complications following FFBR, with postoperative bleeding representing the predominant concern. These findings mandate enhanced perioperative surveillance and bleeding prevention protocols for immunosuppressed patients while supporting the continued feasibility of FFBR in this population when appropriate precautions are implemented.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 4","pages":"Pages 128-136.e1"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147269697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduced Survival Outcomes in Socioeconomically Disadvantaged Women With HER2-Negative Breast Cancer Undergoing Chemotherapy in Canada","authors":"Danilo Giffoni M M Mata ,&nbsp;Italo Fernandes ,&nbsp;Megan Smith-Uffen ,&nbsp;Claire Browne ,&nbsp;Raman Sambhi ,&nbsp;Sara Gehlaut ,&nbsp;Rossanna C Pezo ,&nbsp;Kelvin K W Chan ,&nbsp;Ines Menjak ,&nbsp;Andrea Eisen ,&nbsp;Maureen Trudeau","doi":"10.1016/j.clbc.2026.02.015","DOIUrl":"10.1016/j.clbc.2026.02.015","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer remains the most common oncological condition and the leading cause of cancer-related mortality in the world. In addition to the breast cancer stage at diagnosis, its histology and subtype, the social determinants of health have a substantial role in cancer survivorship.</div></div><div><h3>Methods</h3><div>Utilizing administrative health databases, a retrospective analysis of stage I-III HER2-negative breast cancer was conducted, examining a cohort of 10,634 women treated with surgery and adjuvant chemotherapy in Ontario, Canada.</div></div><div><h3>Results</h3><div>Our study registered a median follow-up of 5.5 years. The 5-year OS ranging from the lowest to the highest socioeconomic status (SES) was (Q1) 91.3%, (Q2) 92.8%, (Q3) 93.0%, (Q4) 92.9% and (Q5) 94.0%. The 5-year OS rate between the SES groups showed (Q5 vs. Q1) HR 0.65 (95% CI, 0.52-0.81), <em>P</em> = .002), (Q4 vs. Q1) HR 0.79 (95% CI, 0.64-0.97, <em>P</em> = .029) and (Q3 vs. Q1) HR 0.75 (95% CI, 0.60-0.94, <em>P</em> = .013). In the analysis of underlying medical conditions, the mean range of the Charlson comorbidity index was Q1 (2.73 ± 2.96) versus Q5 (2.52 ± 2.63), <em>P</em> &lt; .001.</div></div><div><h3>Conclusion</h3><div>Our study shows that there are inequities in the delivery of oncological care amongst women with HER2-negative breast cancer. Those within the lower SES, thereby likely with a socioeconomic disadvantage, exhibited a greater probability of presenting with more advanced cancer staging, were more prone to receive anthracycline-based chemotherapy, while also being confronted with an increased likelihood of significant comorbidities and mortality rates, compared to their wealthier counterparts.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 4","pages":"Pages 158-170.e2"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147497873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Skeletal-Related Events in Bone Metastasis from Advanced Breast Cancer Using Machine Learning","authors":"Hirotaka Miyashita ,&nbsp;Ken Aoshima","doi":"10.1016/j.clbc.2026.01.005","DOIUrl":"10.1016/j.clbc.2026.01.005","url":null,"abstract":"<div><h3>Purpose</h3><div>The purpose of this study is to develop a machine learning (ML) model to predict skeletal-related events (SREs) in patients with bone metastasis from breast cancer.</div></div><div><h3>Patients and Methods</h3><div>Publicly available, patient-level data of patients with bone metastasis from breast cancer receiving zoledronic acid from a previous clinical trial was analyzed. Five feature sets (FS) and seven algorithms were utilized to develop ML models to predict SREs within 18 months. The model was trained with ten-fold cross-validation, repeated three times, and was evaluated through four-fold external cross-validation. Model performances were assessed by multiple metrics and the ability to differentiate cumulative risks of SREs. The model was interpreted by Shapley Additive Explanation. (SHAP)</div></div><div><h3>Results</h3><div>Four hundred sixty cases with bone metastatic breast cancer were incorporated for ML model development. The ML model that utilized six features selected by the Boruta method and random forest algorithm demonstrated the numerically highest performance. (F1 score of 0.70) The mean absolute SHAP values suggested performance status, history of SREs, and serum alkaline phosphatase were the most important features. The ML model differentiated the cases with a high risk and a low risk of SREs, with median time for the first SRE of 248 days and 867 days, respectively. (Hazard ratio: 2.43 and 95% confidence interval: 1.86-3.18)</div></div><div><h3>Conclusion</h3><div>A machine learning model to predict SREs in patients with bone metastatic breast cancer demonstrated the features related to SRE risk and its ability to identify the population with a high risk of SREs.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 4","pages":"Pages 119-127.e2"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Subtype Dictates Survival Outcomes in Encapsulated Papillary Carcinoma of the Breast: A Propensity Score-Matched SEER Analysis Supporting Treatment De-Escalation","authors":"Hongbo Li ,&nbsp;Zhiyong Wang","doi":"10.1016/j.clbc.2026.02.012","DOIUrl":"10.1016/j.clbc.2026.02.012","url":null,"abstract":"<div><h3>Background</h3><div>Encapsulated papillary carcinoma (EPC) is a rare breast malignancy. Controversy persists over its classification and whether its prognosis stems from histology or biology. This study clarified the role of molecular subtypes in EPC prognosis and evaluated treatment de-escalation feasibility.</div></div><div><h3>Patients and Methods</h3><div>EPC and contemporary invasive ductal carcinoma (IDC) patients (2010-2019) were identified from the surveillance, epidemiology, and end results (SEER) database. A 1:1 propensity score matching (PSM) balanced baseline characteristics, including age, grade, stage, and molecular subtype. Breast cancer–specific survival (BCSS) and overall survival (OS) were analyzed using Kaplan–Meier and Cox regression.</div></div><div><h3>Results</h3><div>We included 165 EPC and 247,581 IDC patients. EPC patients were significantly older with lower grade tumors, less nodal involvement, and higher HR+/HER2− proportions (89.7% vs. 71.1%, <em>P</em> &lt; .001). Before matching, EPC showed superior BCSS (<em>P</em> = .044). After PSM (<em>n</em> = 165 per group), no significant differences were observed in BCSS (<em>P</em> = .207) or OS (<em>P</em> = .733) between groups. Subgroup analysis of HR+/HER2− patients yielded consistent results. Chemotherapy usage was low (10.3%) in EPC with excellent outcomes; radiotherapy was an independent protective factor for survival.</div></div><div><h3>Conclusion</h3><div>EPC’s favorable prognosis is primarily driven by its molecular profile (HR+/HER2−) rather than histology. After subtype adjustment, EPC survival is equivalent to IDC. Findings support chemotherapy omission for most EPC patients while emphasizing radiotherapy for local control.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 4","pages":"Pages 150-157.e6"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Event-Free Survival After Stereotactic Body Radiation Therapy for Oligoprogressive Metastatic Breast Cancer","authors":"Riccardo Ray Colciago ,&nbsp;Carlotta Giandini ,&nbsp;Anna Cavallo ,&nbsp;Maria Grazia Carnevale ,&nbsp;Giuseppe Fotia ,&nbsp;Giacomo Mazzoli ,&nbsp;Giulia Valeria Bianchi ,&nbsp;Serena Di Cosimo ,&nbsp;Daniele Presti ,&nbsp;Riccardo Lobefaro ,&nbsp;Laura Lozza ,&nbsp;Maria Carmen De Santis","doi":"10.1016/j.clbc.2025.12.011","DOIUrl":"10.1016/j.clbc.2025.12.011","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;Oligoprogressive advanced breast cancer (aBC) is becoming an increasingly frequent scenario in which prognosis can be meaningfully improved through targeted local interventions. However, evidence is still lacking. In this study, we aimed to evaluate the role of progression-directed radiation therapy (PDRT) in the management of oligoprogressive aBC.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Material and Methods&lt;/h3&gt;&lt;div&gt;We performed a single-institution retrospective analysis of consecutive patients with oligoprogressive aBC who underwent progression-directed radiation therapy (PDRT) between January 2018 and December 2024. Oligoprogression was defined as emergence of up to 5 progressing lesions across a maximum of 3 distinct organs, after at least 1 line of systemic therapy. The primary endpoint was the event-free survival (EFS), defined as interval from the completion of PDRT to one of the following: change of systemic therapy [which is also called time to next treatment (TNT)], progression &lt; 6 months, or ≥ 3 new or progressing lesions, death, or last follow-up. Secondary endpoints included progression-free survival (PFS), and overall survival (OS).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;We analyzed 56 patients, with 17 months [interquartile range (IQR): 8-27] of median follow-up. Median age at PDRT was 58 years (IQR: 49-68). Prior to PDRT, 28 patients (50%) had received only 1 line of treatment, 12 (21.4%) had received 2 lines, and 16 (28.6%) had undergone 3 or more lines. Before the onset of oligoprogression, in response to systemic therapy, 31 patients (55.4%) had achieved stable disease, 9 patients (16.0%) a partial response, and 16 patients (28.6%) a complete response at all disease sites.&lt;/div&gt;&lt;div&gt;In 39 patients (69.6%) an event occurred after PDRT, with a median event free survival (EFS) of 7 months (IQR: 3-15). The 1-year and 2-year actuarial EFS rates were 39% (95% CI, 33.1%-45.9%) and 24% (95% CI, 17.2%-30.8%), respectively. Among these 39 patients, thirty-three (84.6%) initiated a new line of systemic therapy after PDRT, with a median TNT of 8 months (IQR 4-17), with a 1-year actuarial rate of 46.6%. At the multivariate analysis, HER2 positive and Luminal A subtypes were confirmed as significant predictive factors for increased EFS (adjusted HR = 0.31, &lt;em&gt;P&lt;/em&gt; = .01; aHR = 0.27, &lt;em&gt;P&lt;/em&gt; = .01, respectively). Furthermore, lymph nodal PDRT appeared to be associated with a protective effect in the univariate analysis (&lt;em&gt;P&lt;/em&gt; = .04); however, this association was not retained in the multivariate analysis.&lt;/div&gt;&lt;div&gt;Median PFS was 7 months (IQR: 3-12), with 41 patients (73.2%) experiencing disease progression, while the median OS was 17 months (IQR: 8-27). Multivariate analysis confirmed lobular histology as an independent adverse prognostic factor (HR = 9.05, &lt;em&gt;P&lt;/em&gt; = .006).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Our findings suggest that PDRT may delay the occurrence of events and the need to change systemic therapy i","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 3","pages":"Pages 27-38"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146140839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Venous Thromboembolism-Associated Model for Predicting Tumor Microenvironment Features in Breast Cancer","authors":"Zhuoyun Liu ,&nbsp;Shuang Guo ,&nbsp;Xianqun Xu ,&nbsp;Peng Tang ,&nbsp;Han Xue ,&nbsp;Xinghua Long","doi":"10.1016/j.clbc.2026.01.011","DOIUrl":"10.1016/j.clbc.2026.01.011","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer (BC) demonstrates a high worldwide prevalence and remains among the primary contributors to cancer mortality in females. Venous thromboembolism (VTE), a common oncological complication, strongly correlates with poorer survival in BC patients. However, the predictive value of VTE-related genes (VTERGs) in BC prognosis and their impact on clinical outcomes remain underexplored, lacking systematic investigation.</div></div><div><h3>Methods</h3><div>This study developed a novel VTERG-driven predictive framework for BC. Using consensus clustering based on VTERG signatures, we analyzed transcriptomic profiles of BC specimens, identified 2 molecular subtypes, and constructed a prognostic risk model from subtype-specific differentially expressed genes (DEGs). The model was validated in independent datasets. We further compared immune cell infiltration, immunotherapeutic response, somatic mutation patterns, and drug sensitivity between high- and low-risk groups.</div></div><div><h3>Results</h3><div>VTERG-based clustering distinguished 2 BC subtypes with distinct biological features. By screening SERPINA1 and IGHA1 as characteristic genes, a prognostic risk model was developed to achieve robust and independent prediction of BC clinical outcomes. Further integration of clinical covariates confirmed that risk score functioned as an independent prognostic determinant. Following the categorization of patients into high- and low-risk groups, marked disparities were observed between the 2 groups across multiple aspects, including survival prognosis, immune cell infiltration characteristics, human leukocyte antigen expression profiles, immune checkpoint molecular characteristics, and drug sensitivity landscape.</div></div><div><h3>Conclusions</h3><div>The study developed a BC prognostic risk signature that may help predict patient outcomes and offer preliminary insights for personalized immunotherapy strategies.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 3","pages":"Pages 102-118"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147316577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in Survival and Associated Characteristics Between Asian American and White Patients With Breast Cancer","authors":"Yongxin Li ,&nbsp;Dexiang Li ,&nbsp;Xinlong Tao ,&nbsp;Yinyin Ye ,&nbsp;Xiao Liang ,&nbsp;Xingchang Qiu ,&nbsp;Junjie Ma ,&nbsp;Zhibo Liu ,&nbsp;Jiuda Zhao","doi":"10.1016/j.clbc.2026.01.001","DOIUrl":"10.1016/j.clbc.2026.01.001","url":null,"abstract":"<div><h3>Background</h3><div>Extensive research has explored racial differences in breast cancer survival, particularly between Black and White patients. However, few studies have included comparisons with Asian American and White populations.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study using data from the SEER database (2010-2021) for Asian American and White patients with breast cancer. Propensity score matching (PSM) was applied to balance baseline characteristics including age, stage, molecular subtype, and treatment. Survival analyses included Kaplan–Meier (KM) curves, Cox proportional hazards models, and subgroup analyses. Outcomes were overall survival (OS) and breast cancer-specific survival (BCSS).</div></div><div><h3>Results</h3><div>This study included 374,930 patients with breast cancer, with 44,092 Asian American patients with breast cancer and 330,838 White patients with breast cancer. After PSM balanced baseline characteristics, Asian American patients with breast cancer showed significantly better OS (HR = 0.78, 95% CI, 0.75-0.81) and BCSS (HR = 0.88, 95% CI, 0.84-0.93) than White patients with breast cancer. Consistent survival advantages were observed across all clinical and demographic subgroups. After adjustment for key prognostic factors including stage, age, and treatment, Asian American patients with breast cancer remained independently associated with significantly improved survival (OS, HR = 0.77; BCSS, HR = 0.86).</div></div><div><h3>Conclusions</h3><div>Asian American patients with breast cancer demonstrated significantly better survival than White patients with breast cancer after adjusting for multiple factors, with a consistent advantage across subgroups. This suggests intrinsic biological or lifestyle protective factors, warranting further investigation.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 3","pages":"Pages 1-8"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146096063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histiocyte Quantity in Tumor-Negative Sentinel Lymph Nodes Predicts 10-Year Disease-Free Survival in Patients With Breast Cancer","authors":"Sabine Dieleman ,&nbsp;Loes F.S. Kooreman ,&nbsp;Michiel T.H.M. Henkens ,&nbsp;Axel zur Hausen ,&nbsp;Marjolein L. Smidt ,&nbsp;Heike I. Grabsch","doi":"10.1016/j.clbc.2025.11.015","DOIUrl":"10.1016/j.clbc.2025.11.015","url":null,"abstract":"<div><h3>Background and Aim</h3><div>The sentinel lymph node (SLN) play a key role in the host antitumor immune response. Microarchitectural patterns in tumor-negative SLNs (SLNneg) may provide important clinical information about the host’s antitumor immune response against breast cancer.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included SLNneg from 339 breast cancer patients. SLNneg microarchitectural features (percentage (%) SLNneg area occupied by histiocytes, germinal centers, lymphocytes outside germinal centers, adipocytes, vessels or connective tissue) were quantified morphometrically. The relationship with 10-year disease-free survival (DFS) was investigated using Cox regression analyses. Variables showing a nonlinear relationship with survival, cubic spline analysis was used to identify distinct groups.</div></div><div><h3>Results</h3><div>SLNnegs were predominantly occupied by lymphocytes (median % SLNneg area: 60%) followed by histiocytes (14%), vessels (7%), connective tissue (5%), adipocytes (5%) and germinal centers (0.4%). Histiocyte quantity was related to survival in a nonlinear fashion with 9% and 21% as relevant cutoffs. Patients with &lt; 9% or &gt; 21% SLNneg area occupied by histiocytes had poorer survival compared to patients with 9% to 21% SLNneg area occupied by histiocytes (&lt; 9% SLNneg area Hazard Ratio (HR) 2.5 (95% CI, 1.4-4.5), <em>P</em> = .001; &gt; 21% SLNneg area HR 2.7 (1.5;4.7), <em>P</em> &lt; .001; 9% to 21% SLNneg area = ref.), remaining significant in multivariable analysis. The other microarchitectural features were not related to survival.</div></div><div><h3>Conclusion</h3><div>This is the first study showing that quantity of histiocytes in SLNneg is associated with 10-year DFS in breast cancer in a nonlinear manner. This suggests that cell type specific morphological changes within the SLNneg reflect the host’s antitumor immune response providing clinically relevant information in breast cancer patients.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 3","pages":"Pages 247-256.e3"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145833197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}